Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Daptomycin

Nature Reviews Drug Discovery volume 2, pages 943–944 (2003)Cite this article

Abstract

In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Daptomycin.
Figure 2: Market for antibacterial drugs in US $ million in 2002.

References

  1. Coates, A. et al. The future challenges facing the development of new antimicrobial drugs. Nature Rev. Drug Discov. 1, 895–910 (2002).

    Article  CAS  Google Scholar 

  2. Walsh, C. Where will new antibiotics come from? Nature Rev. Microbiol. 1, 65–69 (2003).

    Article  CAS  Google Scholar 

  3. Lowy, F. D. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111, 1265–1273 (2003).

    Article  CAS  Google Scholar 

  4. Tally, F. P. & DeBruin, M. F. Development of daptomycin for Gram-positive infections. J. Antimicrob. Chemother. 46, 523–526 (2000).

    Article  CAS  Google Scholar 

  5. FDA Drug Approvals List [online] (cited 29 October 2003). <http://www.fda.gov/cder/foi/label/2003/21572_cubicin_lbl.pdf> (2003).

  6. Debono, M. et al. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J. Antibiot. (Tokyo) 41, 1093–1105 (1988).

    Article  CAS  Google Scholar 

  7. Fuchs, P. C. et al. In vitro bactericidal acitivity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49, 467–470 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Drug Discovery,

    Aarti Raja, Jason LaBonte, John Lebbos & Peter Kirkpatrick

  2. Decision Resources Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    Aarti Raja, Jason LaBonte, John Lebbos & Peter Kirkpatrick

Authors
  1. Aarti Raja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason LaBonte
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Lebbos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aarti Raja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raja, A., LaBonte, J., Lebbos, J. et al. Daptomycin. Nat Rev Drug Discov 2, 943–944 (2003). https://doi.org/10.1038/nrd1258

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1258

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing